stockrow
Friday 6 November 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025.
- EPS
- −609.4%
- Free cash flow
- −26.5%
Quarter to September 2025, against a year earlier
0.33
0.02
+6.45%
Follow ALPS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to March
| Ten-year view | Analyst estimates Powerpack | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | |||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 2 | 3 | 5 | +42.1% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | 24.92 | 38.60 | 32.09 | +7.2 pt | ||||||
| EBT | — | — | — | — | 0 | 1 | 2 | (1) | (3) | (2) | +77.1% | ||||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (75.03) | (42.86) | (42.9) pt | ||||||
| Net income | 0 | — | — | — | 0 | 0 | 1 | (1) | (3) | (2) | n/m | ||||||
| Per share, $ | |||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | n/m | |||||
| Earnings | — | — | — | — | (0.04) | 0.07 | 0.38 | (0.28) | (0.02) | (0.01) | (20.4%) | ||||||
| Cash flow | — | — | — | — | (0.11) | (0.21) | (0.41) | (0.59) | (0.01) | (0.02) | (32.2%) | ||||||
| Capex | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | (0.11) | (0.21) | (0.41) | (0.59) | (0.01) | (0.02) | (32.0%) | ||||||
| Book value | — | — | — | — | (1.08) | (1.18) | (2.11) | (3.10) | (0.01) | (0.02) | (55.0%) | ||||||
| Shares, m | — | — | — | — | 3 | 3 | 3 | 3 | 160 | 162 | +123.4% | ||||||
| Valuation, × | |||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 144.15 | 0.00 | 0.00 | 48.1 | |||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | (17.11) | (31.47) | (3.21) | (17.3) | ||||||
| Cash, $m | |||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | 0 | (1) | (1) | (2) | (2) | (3) | +51.3% | |||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | 0 | (49.5%) | ||||||
| Free cash flow | — | — | — | — | 0 | (1) | (1) | (2) | (2) | (3) | +52.0% | ||||||
| Balance, $m | |||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 1 | 0 | (4) | (7) | (6) | (4) | n/m | |||||
| Net debt | — | — | — | — | (1) | 0 | 0 | 0 | — | — | (32.2%) | ||||||
| Shareholders’ equity | — | — | — | — | (3) | (4) | (7) | (11) | (1) | (3) | +0.6% | ||||||
| Returns, % | |||||||||||||||||
| Returns, % | ROA | — | — | — | — | (0.10) | 0.19 | 1.79 | (6.01) | (46.40) | (28.48) | (28.4) pt | |||||
| ROIC | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | (0.22) | (6.24) | (23.33) | 10.90 | 42.60 | 92.43 | +92.7 pt | ||||||
| People | |||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 | 0.00 | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Mar 2026 · fundamentals updated 2 Nov 2026
Alps Group Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +300.75% (above 0%: growing) | n/m | −12.69% (below 0%: shrinking) | 82.36% | (303.56%) | Compare |
| HRTX Heron Therapeutics, Inc. | $53.2M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $53.1M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| RNTX Rein Therapeutics Inc. | $52.8M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALPS Alps Group Inc. | $52.3M | — (loss-making) | — | — | n/m | −26.48% (below 0%: shrinking) | — | 0.00% | |
| ELOX Senesco Technologies Inc. | $51.7M | — (loss-making) | — | — | n/m | −144.34% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KLRS Kalaris Therapeutics Inc. | $51.6M | — (loss-making) | — | — | n/m | +11.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| INKT MiNK Therapeutics, Inc. | $51.3M | — (loss-making) | — | — | n/m | −32.73% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| OSTX OS Therapies Incorporated | $51.3M | — (loss-making) | — | — | n/m | −134.43% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $52.2M | — | — | +1.25% | — | −22.71% | 69.28% | 0.00% |